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Deconstructing Type 2 Diabetes Minireview
defectº: insulin resistance or insulin deficiency? WhichSimeon I. Taylor
Diabetes Branch target organ is the most important site of insulin resis-
Division of Intramural Research tance: skeletal muscle, adipose tissue, or liver? Fortu-
National Institute of Diabetes nately, in the midst of controversy, there are some points
and Digestive and Kidney Disease of agreement regarding the pathophysiology of type 2
National Institutes of Health diabetes (Table 1): (1) Genetic factors determine the risk
Bethesda, Maryland 20892 of developing type 2 diabetes. (2) The presence of insulin
resistance predicts future development of type 2 diabe-
tes. (3) Early in the disease, b cells secrete enough insu-
lin to compensate for the insulin resistance and maintainDiabetes mellitus is a major public health problem, af-
a normal level of fasting plasma glucose. Prior to thefecting z5% of the population. The chronic complica-
development of diabetes, fasting hyperglycemia doestions of diabetes cause enormous human suffering in
not develop because insulin prevents excessive hepaticthe form of blindness, kidney failure, amputations, and
increased risk of coronary artery disease and stroke.
Inspired by the desire to develop better therapies, many
researchers have investigated areas of science related
to insulin and diabetes. Nevertheless, despite an impres-
sive number of landmark achievements, many questions
about the causes of diabetes and its chronic complica-
tions remain unanswered.
It Takes a Body to Metabolize Glucose
Over the course of evolution, organisms have evolved
complex mechanisms to regulate fuel metabolism in
response to food availability (Figure 1). Insulin is the
principal hormone that coordinates these processes.
When food is eaten, pancreatic b cells secrete insulin,
which directs the body to store fuel. Insulin promotes
the deposition of glycogen in liver and triglyceride in
adipose tissue, and also activates glucose transport and
glycogen synthesis in muscle. At times of starvation,
insulin levels are low and this directs insulin-sensitive
cells (e.g., muscle, adipose tissue, and liver) to mobilize
stored fuels. Because muscle lacks glucose 6-phospha-
tase, glycogenolysis in muscle does not provide glucose
for release into the blood. However, when insulin levels
are low, muscle exports amino acids and other sub-
strates to the liver for gluconeogenesis.
What Causes Diabetes?
There are two common forms of diabetes:
Type 1 diabetes is caused by autoimmune destruction
of pancreatic b cells, leading to a near total deficiency
in insulin secretion. Patients inject insulin to compensate
for insulin deficiency, but it is not yet possible to mimic
the normal function of the b cell, which precisely adjusts
the rate of insulin secretion in response to biological
needs. Therefore, the treatment of type 1 diabetes is
Figure 1. Insulin Is the Principal Regulator of Energy Metabolismcomplicated all too often by episodes of hypoglycemia
When glucose and other nutrients are absorbed from the gastroin-and hyperglycemia. Unfortunately, hypoglycemia can
testinal tract, this elicits insulin secretion. Insulin regulates the me-cause coma, and hyperglycemia increases the risk of
tabolism of multiple fuels (indicated in blue). Selected actions ofdeveloping diabetic complications such as blindness
insulin are indicated in red (1, activation; 2, inhibition). Insulin acti-
and kidney failure. vates transport of glucose into muscle and adipose tissue, and also
Type 2 diabetes is the most common form of diabetes, promotes synthesis of glycogen and triglycerides. Insulin inhibits
lipolysis in adipose tissue, ketogenesis in liver, and proteolysis inaccounting for .90% of patients. It is caused by two
muscle. Insulin also inhibits hepatic glucose production by inhibitingphysiological defects: resistance to the action of insulin
both glycogenolysis and gluconeogenesis. Insulin does not directlycombined with a deficiency in insulin secretion (De-
regulate the metabolism of red blood cells, which use glycolysis to
Fronzo, 1997). Because the molecular defects causing provide energy. Although the brain uses glucose in the fed state, it
diabetes are not known, this has led to a number of can also use ketone bodies (acetoacetate and 3-hydroxybutyrate)
when levels rise high enough (e.g., during fasting).heated debates in the literature. Which is the ªprimary
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Table 2. Tissue-Specific Inactivation of Insulin ReceptorTable 1. Physiological Defects during Progression from
Prediabetes to Overt Type 2 Diabetesa
Muscle
Muscle Muscle 1 Fat b CellInsulin Insulin Glucose
Resistance Deficiencyc Production K/Oa Dom Negb Dom Negc K/Od
(Muscle) (b Cell) (Liver)
Fasting normal ↑ ↑ normal
glucosePrediabetes
(FPGb , 6.1 mM) 6 2 normal Fasting normal ↑ (/'s) ↑ ↑
insulinImpaired fasting glucose
(FPGb: 6.1±6.9 mM) 1 2 normal Insulin normal Ð insulin Ð
tolerance resistantDiabetes
Mild Glucose normal impaired impaired impaired
tolerance(FPGb: 7.0±7.8 mM) 1 1 normal
Moderate/severe Insulin Ð Ð (6 ↑) ↓ 1st phase
secretion(FPGb . 7.8 mM) 1 1 ↑
a BruÈ ning et al., 1998; b Moller et al., 1996; c Lauro et al., 1998; d Kul-a See DeFronzo (1997) for a more complete discussion of this contro-
versial subject. karni et al., 1999.
b FPG, fasting plasma glucose. Definitions are based upon the most
recent recommendations of the Expert Committee of the American
Diabetes Association. et al., 1997). These transcription factors are expressed
c Definition of insulin deficiency: Insulin levels are lower than in nor- in pancreatic b cells, and the mutations are believed to
mal individuals, either in the fasting state or in response to ingestion cause insulin deficiency by impairing b cell function.
of oral glucose. However, this definition does not exclude the possi- However, because HNFs are also expressed in hepato-
bility that defects in b cell function are present prior to the develop-
cytes, these mutations may cause abnormalities in he-ment of insulin deficiency.
patic glucose metabolism as well.
Insulin Resistance. The insulin receptor, a ligand-stim-
ulated tyrosine kinase, mediates the first steps in insulinglucose production. (See Table 1 for a definition of dia-
action (White and Yenush, 1998). The activated receptorbetes based upon fasting plasma glucose levels.) (4)
phosphorylates multiple proteinsÐe.g., insulin receptorPatients become diabetic if they develop insulin defi-
substrates (IRS)-1, -2, -3, and -4. Phosphorylation ofciency due to failure of the pancreatic b cell. At this
tyrosine residues in these substrates leads to activationpoint in the course of the disease, the degree of hyper-
of multiple downstream signaling pathways. For exam-glycemia is determined by the magnitude of the increase
ple, activation of phosphatidylinositol (PI) 3-kinase trig-in hepatic glucose production.
gers a cascade of serine/threonine protein kinases, in-Deconstructing Diabetes: Genetic Analysis
cluding protein kinase B and atypical isoforms of proteinof Human Diabetes
kinase C, which mediate the metabolic actions of insu-Positional cloning holds great promise for identifying
linÐe.g., stimulation of glucose transport in muscle andgenes that cause the common form of type 2 diabetes
adipose tissue, and regulation of the expression andand for elucidating the molecular mechanisms that
activity of key metabolic enzymes.cause insulin deficiency and insulin resistance. Although
Mutations in the insulin receptor gene, INSR (also
the common form of type 2 diabetes is polygenic, most
known as IR), cause several uncommon syndromes as-
of the progress to date has been in identifying genes
sociated with severe insulin resistance, including lepre-
that cause several uncommon forms of diabetes with chaunism and type A insulin resistance (Taylor, 1992),
monogenic inheritance. but have also been reported in a small percentage of
Insulin Deficiency. The insulin gene was the first gene patients with type 2 diabetes. Amino acid sequence
to be identified as a ªtype 2 diabetes geneº (Steiner et variants have been identified in IRS1, but their role in
al., 1990). Mutations in the insulin gene either inhibit causing diabetes is controversial (Almind et al., 1996;
conversion of proinsulin to insulin or reduce the affinity Imai et al., 1997). Diabetes has not been demonstrated
of insulin for its receptor. Recently, several genes have to be associated with mutations in genes encoding other
been identified as causes of maturity onset±type diabe- proteins in the insulin action pathway. Indeed, when the
tes of youth (MODY), an early-onset form of type 2 diabe- p85a subunit of PI 3-kinase was knocked out, the mice
tes transmitted with autosomal dominant inheritance. developed increased insulin sensitivity and hypoglyce-
MODY2 is caused by mutations in the glucokinase gene mia rather than diabetes (Terauchi et al., 1999).
(Bell et al., 1996). Glucokinase plays an essential role in Reconstructing Diabetes: Studies
the glucose-sensing mechanism of b cells, and muta- of Genetically Engineered Mice
tions in this gene lead to a partial deficiency of insulin Animal models of disease do not prove which genes
secretion. In mouse models, b cell±specific knockout of are actually mutated in human disease. However, by
one allele of the glucokinase gene closely replicated inserting mutations into specific genes, one can eluci-
the features of MODY2, but genetic defects in hepatic date the impact of those mutations. This approach has
glucokinase may also contribute to the metabolic defect been applied to construct animal models of diabetes.
(Terauchi et al., 1995; Postic et al., 1999). Homozygous insulin receptor knockout mice develop
In other forms of MODY, mutations have been identi- severe insulin resistance and uncontrolled diabetes (Ac-
fied in various transcription factors: hepatocyte nuclear cili et al., 1996; Joshi et al., 1996). Although these mice
factor (HNF)-4a, HNF-1a, insulin promoter factor-1, and die within the first days of life, viable mice have been
HNF-1b in MODY1, -3, -4, and -5, respectively (Yama- obtained in which the insulin receptor knockout was
limited to specific tissues (Table 2).gata et al., 1996a, 1996b; Stoffers et al., 1997; Horikawa
Minireview
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Skeletal Muscle. Insulin receptor function has been insulin action and insulin secretion. bIRKO mice exhib-
ited a defect in the ability of glucose to elicit insulininhibited in two ways: muscle-specific knockout of the
secretion, leading to progressive impairment in glucoseinsulin receptor (MIRKO; BruÈ ning et al., 1998) and mus-
tolerance (Kulkarni et al., 1999). Two mechanisms havecle-specific expression of a dominant-negative mutant
been identified to explain how insulin receptors promoteinsulin receptor (IR-A1134T) in transgenic mice (Moller
insulin secretion in b cells. Insulin stimulates exocytosiset al., 1996). In both models, skeletal muscle was insulin
of secretory vesicles (Aspinwall et al., 1999); exocytosisresistant when studied in vitro. Also, fat depots were
of insulin feeds back to promote transcription of theincreased in sizeÐpresumably because glucose was
insulin gene, an effect mediated by insulin receptors,shunted from insulin-resistant muscle to adipose tissue
IRS2, and PI 3-kinase (Leibiger et al., 1998). This rolewhere it was converted into triglyceride for storage.
for IRS2 in b cells helps to explain the observation thatHowever, the two mouse models were not identical.
IRS2 knockout mice developed diabetes because of aWhereas MIRKO mice had normal fasting glucose levels
failure of insulin secretion to compensate for insulin re-and normal glucose tolerance (BruÈ ning et al., 1998), IR-
sistance (Withers et al., 1998). However, the role of IRS2A1134T mice had mildly elevated glucose levels both
in b cells may not be limited to the insulin action pathwayduring fasting and throughout the glucose tolerance test
because IRS molecules also function in signaling path-(i.e., a test in which glucose levels are measured at
ways downstream from receptors for cytokines and in-multiple time points after glucose has been administered
sulin-like growth factors.to the animal) (Moller et al., 1996). Differences in genetic
Of Mice and Menbackground may contribute to the apparent differences
There is a natural temptation to extrapolate insights frombetween the two types of genetically engineered mice.
these animal models to explain the pathophysiology ofAlternatively, the dominant-negative mutant receptor
human diabetes. In some cases, the animal modelmight block signaling through other receptors in addi-
closely resembles the human disease, as is the case withtion to the insulin receptor.
glucokinase knockout mice and MODY2. In contrast,Lauro et al. (1998) expressed a dominant-negative
insulin receptor knockout mice differ dramatically frommutant insulin receptor (IR-K1030M) in both muscle and
patients with leprechaunism, the human disease re-adipose tissue of transgenic mice. When expressed in
sulting from absence of insulin receptors (Elders et al.,mice that were also heterozygous for a null allele of the
1982; Taylor, 1992). While insulin receptor knockoutendogenous insulin receptor (Insr) gene, the K1030M
mice develop a severe form of diabetes associated withmutant receptor caused insulin resistance in both tis-
marked hyperglycemia and ketoacidosis, patients withsues. Like IR-A1134T mice (but unlike MIRKO mice),
leprechaunism exhibit relatively mild hyperglycemia.transgenic Insr1/2,K1030M mice developed mild fasting hy-
Furthermore, intrauterine growth retardation, a key fea-perglycemia and impaired glucose tolerance.
ture of the human disease, was not found in the knockoutWhy does insulin resistance in muscle have such a
mouse. Why might the same mutation cause differentsmall effect upon the level of fasting glucose? To answer
phenotypes in different species? There may be differ-this question, it is necessary to review the role of muscle
ences in the genetic background; for example, parallel orin glucose metabolism. In the fasting state when insulin
redundant pathways may vary in importance in differentlevels are low, muscle oxidizes fatty acids rather than
species. Indeed, there can be striking differences inglucose as its principal fuel source. Because muscle is
phenotype even when a specific mutation is introducedresponsible for such a small percentage of total glucose
into different strains of mice. By mapping and ultimatelyutilization during fasting, a reduction in muscle glucose
cloning modifier genes that account for variations inuptake does not cause a major change in the fasting
phenotype, we will advance our understanding of poly-glucose level. Furthermore, studies of patients with insu-
genic diseases such as diabetes.lin-secreting tumors suggest that inhibition of hepatic
The differences between insulin receptor knockout
glucose production is the major mechanism whereby
mice and the corresponding human disease invite the
insulin lowers plasma glucose in the fasting state. Con-
question: Are mice with tissue-specific insulin resis-
sequently, because muscle-specific knockout of insulin tance good models for human disease?
receptors does not impair insulin action upon the liver, Insulin resistance in skeletal muscle. The phenotype
injection of insulin elicits a normal decrease in plasma of mice with insulin resistance at the level of muscle
glucose in MIRKO mice. Nevertheless, there appear to (Moller et al., 1996; BruÈ ning et al., 1998) closely resem-
be two mechanisms whereby insulin acts upon the liver: bles an early stage of human type 2 diabetes (DeFronzo,
a direct mechanism and an indirect mechanism. As sug- 1997). Like ªprediabeticº humans, these mice exhibit
gested by Bergman (1997), the indirect mechanism may insulin resistance at the level of muscle, but maintain
mediate the effect of insulin to inhibit hepatic glucose normal (or only minimally elevated) fasting plasma glu-
production. Insulin first acts directly upon adipose tissue cose levels. Unlike the animal models, the precise mo-
to suppress lipolysis and decrease levels of circulating lecular cause of insulin resistance has not yet been eluci-
free fatty acids. This, in turn, may cause the inhibition dated in humans although it is known that there is a
of hepatic glucose production. Tissue-specific knock- block at the level of glucose uptake/phosphorylation in
outs of insulin receptors in liver and adipose tissue may muscle of patients with type 2 diabetes.
shed light on the relative importance of the direct versus Insulin resistance in pancreatic b cells. Because insu-
indirect pathways of insulin action in liver. lin resistance develops early in the natural history of
Pancreatic b Cells. Elegant studies of mice with b type 2 diabetes, it has long been suspected that insulin
cell±specific knockout of the insulin receptor (bIRKO) resistance may play a causal role in the development
of the defect in insulin secretion. Novel insights providedhave yielded novel insights into the relationship between
Cell
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Baldwin, D., Fiser, R., Seyedabadi, S., and Rubenstein, A. (1982). J.by bIRKO mice suggest a unified theory to explain the
Natl. Med. Assoc. 74, 1195±1210.pathogenesis of type 2 diabetes. A genetic defect in the
Horikawa, Y., Iwasaki, N., Hara, M., Furuta, H., Hinokio, Y., Cockburn,insulin action pathway may not only cause target cells
B., Lindner, T., Yamagata, K., Ogata, M., Tomonaga, O., et al. (1997).to become insulin resistant, but also might directly cause
Nat. Genet. 17, 384±385.
b cell failure and insulin deficiency.
Imai, Y., Philippe, N., Sesti, G., Accili, D., and Taylor, S.I. (1997). J.
However, Kulkarni et al. (1999) identified an important Clin. Endocrinol. Metab. 82, 4201±4207.
difference in phenotypes between bIRKO mice and hu-
Joshi, R., Lamothe, B., Cordonnier, N., Mesbah, K., Monthioux, E.,
man patients. Whereas insulin secretion is impaired in Jami, J., and Bucchini, D. (1996). EMBO J. 15, 1542±1547.
bIRKO mice, humans with mutations in the insulin recep- Kulkarni, R., BruÈ ning, J.C., Winnay, J., Postic, C., Magnuson, M.,
tor gene (e.g., patients with leprechaunism) exhibit strik- and Kahn, C. (1999). Cell 96, 329±339.
ing hyperplasia of pancreatic islets and hypersecretion Lauro, D., Kido, Y., Castle, A., Zarnowski, M., Hayashi, H., Ebina,
of insulin (Elders et al., 1982). Furthermore, even in mice, Y., and Accili, D. (1998). Nat. Genet. 20, 294±298.
a defect in insulin signaling does not necessarily cause Leibiger, I., Leibiger, B., Moede, T., and Berggren, P. (1998). Mol.
Cell 1, 933±938.deficiency in insulin secretion. BruÈ ning et al. (1997) engi-
neered mice to become insulin resistant by introducing Moller, D., Chang, P., Yaspelkis, B. 3., Flier, J., Wallberg-Henriksson,
H., and Ivy, J. (1996). Endocrinology 137, 2397±2405.heterozygous null mutations into both the Insr gene and
Postic, C., Shiota, M., Niswende, K., Jetton, T., Chen, Y., Moates,the Irs1 gene; these Insr1/2Irs11/2 mice developed strik-
J., Shelton, K., Lindner, J., Cherrington, A., and Magnuson, M. (1999).ing hyperplasia of b cells. Interestingly, the phenotype
J. Biol. Chem. 274, 305±315.of b cell hyperplasia observed in the Insr1/2Irs11/2 mice
Steiner, D.F., Tager, H.S., Chan, S.J., Nanjo, K., Sanke, T., and Ru-closely resembles the phenotype of patients with lepre-
benstein, A.H. (1990). Diabetes Care 13, 600±609.chaunism. Furthermore, Insr1/2Irs11/2 mice, like most
Stoffers, D., Ferrer, J., Clarke, W., and Habener, J. (1997). Early-patients with type 2 diabetes, exhibit generalized, partial
onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat. Genet.
insulin resistance rather than the total, tissue-specific 17, 138±139.
insulin resistance of bIRKO mice. Thus, there appear Taylor, S.I. (1992). Diabetes 41, 1473±1490.
to be complex interactions between insulin signaling
Terauchi, Y., Sakura, H., Yasuda, K., Iwamoto, K., Takahashi, N.,
and b cell function; depending upon the circumstances, Ito, K., Kasai, H., Suzuki, H., Ueda, O., Kamada, N., et al. (1995). J.
insulin resistance may lead either to insulin deficiency Biol. Chem. 270, 30253±30256.
(as in bIRKO mice) or to b cell hyperplasia plus hyper- Terauchi, Y., Tsuji, Y., Satoh, S., Minoura, H., Murakami, K., Okuno,
insulinemia (as in humans with leprechaunism and A., Inukai, K., Asano, T., Kaburagi, Y., Ueki, K., et al. (1999). Nat.
Genet. 21, 230±235.Insr1/2Irs11/2 mice).
White, M.F., and Yenush, L. (1998). Curr. Top. Microbiol. Immunol.Because type 2 diabetes is a complex heterogeneous
228, 179±208.disease with multiple genes contributing to the cause
Withers, D., Gutierrez, J., Towery, H., Burks, D., Ren, J., Previs, S.,of this polygenic disorder, it is likely that these murine
Zhang, Y., Bernal, D., Pons, S., Shulman, G., Bonner-Weir, S., andanimal models will shed light on disease mechanisms
White, M. (1998). Nature 391, 900±904.that contribute to the pathophysiology of human diabe-
Yamagata, K., Furuta, H., Oda, N., Kaisaki, P.J., Menzel, S., Cox,tes. Defects in the insulin action pathway may be the
N.J., Fajans, S.S., Signorini, S., Stoffel, M., and Bell, G.I. (1996a).
cause of insulin deficiency in some patients, but there Nature 384, 458±460.
may also be patients in whom there are primary genetic Yamagata, K., Oda, N., Kaisaki, P.J., Menzel, S., Furuta, H., Vaxillaire,
defects that directly impair the machinery for insulin M., Southam, L., Cox, R.D., Lathrop, G.M., Boriraj, V.V., et al. (1996b).
secretion. The approach of positional cloning, currently Nature 384, 455±458.
underway in several laboratories, holds great promise
to resolve these controversies by directly identifying
the genes that cause both insulin deficiency and insulin
resistance.
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